<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02291601</url>
  </required_header>
  <id_info>
    <org_study_id>R13-052</org_study_id>
    <nct_id>NCT02291601</nct_id>
  </id_info>
  <brief_title>Preoperative CHG Cloth on Healthy Subjects</brief_title>
  <official_title>Assessment of the Antimicrobial Efficacy of 2% CHG Cloth Preoperative Skin Preparation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medline Industries</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medline Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the effects of CHG cloth on the reduction of bacteria on the skin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Examine the antimicrobial cloth effects on normal flora bacteria of the abdomen and groin&#xD;
      area post CHG application.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Responder Rates of Bacterial Reduction on the Abdomen and Groin Sites</measure>
    <time_frame>10 minutes to 8 hours</time_frame>
    <description>Percent of abdomen and groin sites that achieve a 2-Log or 3-Log reduction respectively of bacterial flora from baseline.&#xD;
Note: The number of participants in each treatment group (abdomen and/or groin) can vary depending on whether participants achieved qualifying microbial levels on the abdomen and groin at baseline.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">879</enrollment>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>Chlorhexidine Gluconate Cloth</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2% CHG, single application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Cloth</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Excipients on cloth</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active Chlorhexidine gluconate solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dynahex 2% CHG</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorhexidine Gluconate</intervention_name>
    <description>comparison with other CHG products</description>
    <arm_group_label>Chlorhexidine Gluconate Cloth</arm_group_label>
    <other_name>CHG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Excipients of CHG product only.</description>
    <arm_group_label>Vehicle Cloth</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DynaHex-2</intervention_name>
    <description>2% CHG solution</description>
    <arm_group_label>Active Chlorhexidine gluconate solution</arm_group_label>
    <other_name>CHG 2% Solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or Females&#xD;
&#xD;
          -  16 years of age or older&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Good Health&#xD;
&#xD;
          -  Six inches of abdomen and groin areas without tattoos, or skin disorders&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dermatological Conditions&#xD;
&#xD;
          -  Sensitivity to latex&#xD;
&#xD;
          -  Sensitivity to CHG&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C Beausoleil</last_name>
    <role>Principal Investigator</role>
    <affiliation>BS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BioScience</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 11, 2014</study_first_submitted>
  <study_first_submitted_qc>November 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2014</study_first_posted>
  <results_first_submitted>February 3, 2016</results_first_submitted>
  <results_first_submitted_qc>April 29, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 30, 2021</results_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Preoperative surgical skin preparation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data to be shared with FDA</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Upon achieving sufficient microbial growth prior to product application on either the abdomen, groin or both abdomen and groin regions, sites of the participant were then randomized to receive one or two products for evaluation for up 4 sites. Differences in the number of participants is based on microbial qualification.</recruitment_details>
      <pre_assignment_details>The sites of the participant were tested for microbial activity after product application. In some instances, more than one product could have been applied to a participant but only one product per site (groin and/or abdomen sites). Up to 4 sites could be treated : 1) both groin and abdomen, 2) only the groin or 3) only the abdomen.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CHG Cloth</title>
          <description>CHG 3 min application</description>
        </group>
        <group group_id="P2">
          <title>Vehicle</title>
          <description>Vehicle, 3 min application</description>
        </group>
        <group group_id="P3">
          <title>Comparator CHG</title>
          <description>marketed CHG - application done per products instructions for use</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Abdomen</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="638"/>
                <participants group_id="P2" count="108"/>
                <participants group_id="P3" count="642"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="305">638 participants received CHG cloth</participants>
                <participants group_id="P2" count="54">108 participants received vehicle</participants>
                <participants group_id="P3" count="303">642 participants received comparator CHG</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="333"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="339"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not qualify</title>
              <participants_list>
                <participants group_id="P1" count="333"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="339"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Groin</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="520"/>
                <participants group_id="P2" count="93"/>
                <participants group_id="P3" count="515"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="337">520 participants received CHG cloth</participants>
                <participants group_id="P2" count="63">93 participants received vehicle</participants>
                <participants group_id="P3" count="338">515 participants received Comparator CHG</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="183"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="177"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Did not qualify</title>
              <participants_list>
                <participants group_id="P1" count="183"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="177"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Overall Number of Baseline Participants represents the total number of participants that qualified and were tested.</population>
      <group_list>
        <group group_id="B1">
          <title>CHG, Vehicle, Comparator CHG</title>
          <description>Single applications of products. 3 min application for CHG and vehicle. Comparator CHG applied according to instructions.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="879"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="829"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" lower_limit="16" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="281"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="879"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Responder Rates of Bacterial Reduction on the Abdomen and Groin Sites</title>
        <description>Percent of abdomen and groin sites that achieve a 2-Log or 3-Log reduction respectively of bacterial flora from baseline.&#xD;
Note: The number of participants in each treatment group (abdomen and/or groin) can vary depending on whether participants achieved qualifying microbial levels on the abdomen and groin at baseline.</description>
        <time_frame>10 minutes to 8 hours</time_frame>
        <population>Participants received 1 or 2 products on up to 2 abdomen and 2 groin sites, 2 abdomen only sites or 2 groin sites only.</population>
        <group_list>
          <group group_id="O1">
            <title>CHG Abdomen</title>
            <description>single application on abdomen</description>
          </group>
          <group group_id="O2">
            <title>CHG Groin</title>
            <description>single application on groin.</description>
          </group>
          <group group_id="O3">
            <title>Vehicle Abdomen</title>
            <description>single application on abdomen</description>
          </group>
          <group group_id="O4">
            <title>Vehicle Groin</title>
            <description>single application on groin</description>
          </group>
          <group group_id="O5">
            <title>Comparator Abdomen</title>
            <description>single application on abdomen</description>
          </group>
          <group group_id="O6">
            <title>Comparator Groin</title>
            <description>single application of groin</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Responder Rates of Bacterial Reduction on the Abdomen and Groin Sites</title>
          <description>Percent of abdomen and groin sites that achieve a 2-Log or 3-Log reduction respectively of bacterial flora from baseline.&#xD;
Note: The number of participants in each treatment group (abdomen and/or groin) can vary depending on whether participants achieved qualifying microbial levels on the abdomen and groin at baseline.</description>
          <population>Participants received 1 or 2 products on up to 2 abdomen and 2 groin sites, 2 abdomen only sites or 2 groin sites only.</population>
          <units>% of Treated Sites</units>
          <param>Number</param>
          <units_analyzed>sites</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="337"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="303"/>
                <count group_id="O6" value="338"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>sites</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="337"/>
                <count group_id="O3" value="54"/>
                <count group_id="O4" value="60"/>
                <count group_id="O5" value="303"/>
                <count group_id="O6" value="338"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>10 min</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                    <measurement group_id="O2" value="75"/>
                    <measurement group_id="O3" value="86"/>
                    <measurement group_id="O4" value="65"/>
                    <measurement group_id="O5" value="81"/>
                    <measurement group_id="O6" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="97"/>
                    <measurement group_id="O4" value="100"/>
                    <measurement group_id="O5" value="96"/>
                    <measurement group_id="O6" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="97"/>
                    <measurement group_id="O4" value="100"/>
                    <measurement group_id="O5" value="96"/>
                    <measurement group_id="O6" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Qualified and disqualified participants were included in the safety analysis for each treatment group as all of these participants were exposed to one or two different products. In those cases where one participant received 2 products at the same time (on different sites), participants were represented for both products.</desc>
      <group_list>
        <group group_id="E1">
          <title>CHG Cloth</title>
          <description>single application</description>
        </group>
        <group group_id="E2">
          <title>Vehicle</title>
          <description>Excipients of CHG product only.</description>
        </group>
        <group group_id="E3">
          <title>Comparator CHG</title>
          <description>2% CHG solution</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="753"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="755"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="136"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="753"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="753"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skin Abrasion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="753"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="753"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="753"/>
              </event>
              <event>
                <sub_title>Irritation skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="753"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="755"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="753"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Confidential information based on contract</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>C Beausoleil</name_or_title>
      <organization>Bioscience Labs</organization>
      <phone>460-782-5498</phone>
      <email>cbeausoleil@biosciencelabs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

